Summary & Overview
HCPCS Level II J9342: Thiotepa Injection, 1 mg
HCPCS Level II code J9342 designates a 1 mg unit of thiotepa administered by injection for oncologic treatment. As a drug-specific HCPCS code, it is used on medical claims to report the billed quantity of thiotepa supplied and administered. Accurate reporting of J9342 matters nationally because chemotherapy drug coding affects drug expenditure tracking, benefit design application, and medical necessity adjudication across payers.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for thiotepa use, typical sites of service where this code is billed, and the common claim-level considerations for HCPCS drug coding. The publication provides benchmarking context and coding operational notes relevant to billing teams, revenue cycle managers, and specialty providers.
The document summarizes typical billing practices and payer coverage patterns, highlights common modifiers used with HCPCS drug codes, and outlines where to look for policy updates affecting chemotherapy drug reimbursement. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J9342 describes an injection of thiotepa, specified as not otherwise specified, billed per 1 mg. This code represents administration of the chemotherapeutic agent thiotepa for oncologic indications.
Service type: Injection, chemotherapy agent delivery
Typical site of service: Hospital outpatient department, clinic infusion center, or physician office infusion suite
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult oncology patient receiving chemotherapy for systemic malignancy such as bladder cancer, breast cancer, or lymphoma. The treatment plan includes administration of J9342 (thiotepa) as an intravenous or intravesical chemotherapeutic agent. The clinical workflow begins with oncologist evaluation and order entry, pharmacy verification and compounding of the J9342 dose in an appropriate sterile environment, and nursing administration in an infusion center, hospital outpatient department, or ambulatory surgical center. Pre‑administration steps include review of diagnosis and prior therapies, verification of body surface area or weight for dosing, assessment of baseline labs (CBC, renal and hepatic function), and consent. During administration, nursing monitors for infusion reactions, extravasation risk, and immediate toxicities; supportive medications (antiemetics, hydration) are provided as indicated. Post‑administration monitoring includes observation for delayed myelosuppression, infection risk education, and scheduling of follow‑up labs and oncology visits. Typical sites of service are hospital outpatient infusion centers, physician offices with chemotherapy capability, and ambulatory infusion centers. Common patient scenarios include adjuvant, neoadjuvant, or palliative chemotherapy regimens where thiotepa is included as a single agent or part of combination therapy; intravesical use for bladder instillation is an alternate site‑specific scenario requiring procedural setup and local monitoring.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|